“We acknowledge there are significant challenges involved in securing reimbursement for innovative medicines in Australia, and our focus in the near term is on enabling private access so patients are not left waiting without options," said Manny Simons, General Manager of Lilly Australia and New Zealand.
Lilly therapy approved in Australia as first non-covalent BTK inhibitor for common blood cancer
May 5, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Entropy Neurodynamics clears safety hurdle for IV psilocin trial in binge eating disorder
June 15, 2026 - - Australian Biotech -
Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment
June 15, 2026 - - Australian Biotech -
High Court to decide on patent‑term extensions for formulations as GBMA intervenes
June 15, 2026 - - Latest News -
Approach policy and pricing negotiations like planning for a product launch
June 15, 2026 - - Latest News -
The 'Dispatched' Week in Review'- 14 June
June 15, 2026 - - Podcast -
LifeSciences Australia honours outstanding professionals at MTP Sector Awards 2026
June 12, 2026 - - Latest News -
State and Territory ministers warn against centralising NDIS power
June 12, 2026 - - Latest News

